NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03748134,Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ),https://clinicaltrials.gov/study/NCT03748134,,COMPLETED,"This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.

After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in subjects representing the western population with advanced esophageal squamous cell carcinoma",NO,Esophageal Squamous Cell Carcinoma,BIOLOGICAL: Sintilimab|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Fluorouracil|DRUG: Placebo,"OS in overall population, To compare the overall survival of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), From date of randomization until the date of death from any cause, assessed up to 40 months.|OS in PD-L1 positive population, To compare the OS of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with PD-L1 positive, unresectable, locally advanced, recurrent or metastatic ESCC, From date of randomization until the date of death from any cause, assessed up to 40 months.","ORR in overall population, To compare the objective response rate between the two treatment arms in ITT population, From date of randomization up to 28 months.|PFS in overall populationsubjects in ITT population, To compare the progression-free survival between the two treatment arms in ITT population, From date of randomization up to 28 months|DCR in overall population, To compare the disease control rate between the two treatment arms in ITT population, From date of randomization up to 28 months|DoR in overall population, To compare the duration of response between the two treatment arms in ITT population, From date of randomization up to 28 months|ORR - PD-L1 positive, To compare the objective response rate between the two treatment arms in PD-L1 positive subjects in ITT population, From date of randomization up to 28 months|DCR - PD-L1 positive, To compare the disease control rate between the two treatment arms in PD-L1 positive subjects in ITT population, From date of randomization up to 28 months|DoR - PD-L1 positive, To compare the duration of response between the two treatment arms in PD-L1 positive subjects in ITT population, From date of randomization up to 28 months|PFS - PD-L1 positive, To compare the progression-free survival between the two treatment arms in PD-L1 positive subjects in ITT population, From date of randomization up to 28 months",,Innovent Biologics (Suzhou) Co. Ltd.,Fortrea,ALL,"ADULT, OLDER_ADULT",PHASE3,746,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CIBI308A301|2020-000533-40,2018-12-24,2021-09-09,2023-07-29,2018-11-20,,2023-10-24,"St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center, Anaheim, California, 92835, United States|UC Irvine, Orange, California, 92868, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, 80218, United States|IACT Health - John B. Amos Cancer center, Columbus, Georgia, 31904, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Texas Oncology, P.A., Austin, Texas, 78705, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, 98684, United States|Border Medical Oncology, East Albury, New South Wales, 2640, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, 5011, Australia|Austin Hospital, Heidelberg, Victoria, 3079, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, 6008, Australia|University Hospital Gent, Gent, Corneel Heymanslaan 10, 9000, Belgium|Universitair Ziekenhuis Leuven, Leuven, Herestraat 49, 3000, Belgium|Cliniques Universitaires Saint-Luc Av., Bruxelles, Hippocrate 10, 1200, Belgium|Institut Jules Bordet, Brussels, 1000, Belgium|Centre Hospitalier Regional de Verviers, Verviers, 4800, Belgium|Beijing Cancer Hospital, Beijing, China|Hôpital Jean Minjoz, Bettancourt La Ferree, 25000, France|Institut Bergonié, Bordeaux, 33000, France|Centre François Baclesse, Caen, 14000, France|CHU Estaing, Clermont Ferrand, 63000, France|CHU Estaing, Clermont Ferrand, 63100, France|Faculte de Medecine, Dijon, 21000, France|Universite de Bourgogne - Faculte de Medecine - INSERM U866, Dijon, 21079, France|Oscar Lambret Centre, Lille, 59020, France|CHU Hôpital de la Timone, Marseille, 13005, France|Hôpital Européen Georges Pompidou, Paris, 75015, France|CHU de Poitiers, Poitiers, 86021, France|Hôpital Charles-Nicolle de Rouen, Rouen, 76000, France|Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, 54500, France|Országos Onkológiai Intézet, Budapest, Ráth György U. 7-9, 1122, Hungary|Jósa András Oktatókórház, Nyíregyháza, Szent István U. 68, 4400, Hungary|University Hospital Marqués de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital del Mar, Barcelona, 08001, Spain|Hospital Universitario Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, 28942, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, 25198, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, 280402, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, 31008, Spain|Parc Taulí Sabadell Hospital Universitari, Sabadell, 08208, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, 15706, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41003, Spain|Consorci Hospital General Universitari de València, Valencia, 46016, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain",
